Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-06-02

Clinical Trial Update: Open-label Extension to Protocol 1042-0500 [Phase 2]

View source ↗

Summary

An open-label extension to Protocol 1042-0500 (Phase 2) in infantile spasms was terminated. Results from the extension were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ganaxolone (Ztalmy) (ganaxolone)

Snippet

Sponsor: Marinus Pharmaceuticals | Conditions: Infantile Spasms | Phase 2 | Status: TERMINATED | Results posted: 2023-06-02